We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

114 hedge funds and large institutions have $78.4M invested in Akebia Therapeutics in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more call options, than puts

Call options by funds: $910K | Put options by funds: $472K

73% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 15

37% more capital invested

Capital invested by funds: $57.4M → $78.4M (+$21M)

28% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 25

11% more funds holding

Funds holding: 103 → 114 (+11)

1.41% more ownership

Funds ownership: 26.85% → 28.26% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
114
Holders Change
+11
Holders Change %
+10.68%
% of All Funds
1.64%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
26
Increased
32
Reduced
25
Closed
15
Calls
$910K
Puts
$472K
Net Calls
+$438K
Net Calls Change
-$159K

Top Buyers

1
BlackRock
BlackRock
New York
+$4.75M
2
Northern Trust
Northern Trust
Illinois
+$1.6M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.06M
4
State Street
State Street
Massachusetts
+$912K
5
Wellington Management Group
Wellington Management Group
Massachusetts
+$540K

Top Sellers

1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$4.14M
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$562K
3
Citadel Advisors
Citadel Advisors
Florida
-$287K
4
Renaissance Technologies
Renaissance Technologies
New York
-$263K
5
Marshall Wace
Marshall Wace
United Kingdom
-$252K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$20.1M +$4.75M +3,558,723 +31%
Vanguard Group
2
Vanguard Group
Pennsylvania
$13.3M +$1.06M +794,035 +9%
AIM
3
Alerce Investment Management
Illinois
$7.59M – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$6.28M +$291K +218,172 +5%
Renaissance Technologies
5
Renaissance Technologies
New York
$4.91M -$263K -197,000 -5%
State Street
6
State Street
Massachusetts
$4.53M +$912K +683,287 +25%
Jacobs Levy Equity Management
7
Jacobs Levy Equity Management
New Jersey
$2.69M -$80.9K -60,564 -3%
Northern Trust
8
Northern Trust
Illinois
$2.16M +$1.6M +1,198,213 +274%
Qube Research & Technologies (QRT)
9
Qube Research & Technologies (QRT)
United Kingdom
$1.75M -$562K -420,887 -24%
Morgan Stanley
10
Morgan Stanley
New York
$1.44M +$435K +325,560 +43%
Connor, Clark & Lunn Investment Management (CC&L)
11
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$1.38M +$844 +632 +0.1%
Federated Hermes
12
Federated Hermes
Pennsylvania
$1.15M +$3.7K +2,769 +0.3%
Fidelity Investments
13
Fidelity Investments
Massachusetts
$900K +$188K +140,529 +26%
Charles Schwab
14
Charles Schwab
California
$751K -$3.08K -2,307 -0.4%
Goldman Sachs
15
Goldman Sachs
New York
$641K +$182K +136,351 +39%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$620K -$180K -134,843 -22%
Wellington Management Group
17
Wellington Management Group
Massachusetts
$534K +$540K +404,718 New
N
18
Nuveen
North Carolina
$502K – – –
Barclays
19
Barclays
United Kingdom
$360K +$268K +200,482 +276%
Bank of America
20
Bank of America
North Carolina
$329K +$29.9K +22,429 +10%
RhumbLine Advisers
21
RhumbLine Advisers
Massachusetts
$321K -$5.59K -4,184 -2%
SC
22
Sapient Capital
Indiana
$264K – – –
Two Sigma Advisers
23
Two Sigma Advisers
New York
$248K +$48.1K +36,000 +24%
Russell Investments Group
24
Russell Investments Group
United Kingdom
$225K -$7.25K -5,428 -3%
Franklin Resources
25
Franklin Resources
California
$221K +$223K +167,184 New
1
2 3 4 5

AKBA Hedge Fund Activity: Q3 2024 in Review

114 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2024, worth a combined $78.4M — up 37% from $57.4M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AKBA positions and 15 closed out — a net gain of 11 holders — while 32 added to existing stakes and 25 trimmed.

The largest buyer was BlackRock, adding an estimated $4.75M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $4.14M sold.

  • 114 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2024, up from 103 in Q2 2024.
  • Funds reported $78.4M of Akebia Therapeutics stock for Q3 2024, up 37% quarter-over-quarter.
  • 26 funds opened new Akebia Therapeutics positions in Q3 2024 and 15 closed out, a net change of +11 holders.
  • The largest Akebia Therapeutics buyer in Q3 2024 was BlackRock, an estimated $4.75M added.
  • The largest Akebia Therapeutics seller in Q3 2024 was Acadian Asset Management, an estimated $4.14M sold.

Based on aggregated 13F filings for Q3 2024.